It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Breast cancer (BC) is a major contributor to female mortality worldwide, particularly in young women with aggressive tumors. Despite the need for accurate prognosis in this demographic, existing studies primarily focus on broader age groups, often using the SEER database, which has limitations in variable selection. This study aimed to develop an ML-based model to predict survival outcomes in young BC patients using the BC public staging database. A total of 3,401 patients with BC were included in the study. Patients were categorized as younger (n = 1574) and older (n = 1827). We applied several survival models—Random Survival Forest, Gradient Boosting Survival, Extra Survival Trees (EST), and penalized Cox models (Lasso and ElasticNet)—to compare mortality characteristics. The EST model outperformed others in predicting mortality for both age groups. Older patients exhibited a higher prevalence of comorbidities compared to younger patients. Tumor stage was the primary variable used to train the model for mortality prediction in both groups. COPD was a significant variable only in younger patients with BC. Other variables exhibited varying degrees of consistency in each group. These findings can help identify high-risk young female patients with BC who require aggressive treatment by predicting the risk of mortality.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hanyang University, Department of Applied Artificial Intelligence, Ansan-si, Republic of Korea (GRID:grid.49606.3d) (ISNI:0000 0001 1364 9317); National Cancer Center, Department of Cancer AI & Digital Health, Graduate School of Cancer Science and Policy, Goyang-si, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)
2 Hanyang University, Department of Applied Artificial Intelligence, Ansan-si, Republic of Korea (GRID:grid.49606.3d) (ISNI:0000 0001 1364 9317)
3 National Cancer Center, Department of Cancer AI & Digital Health, Graduate School of Cancer Science and Policy, Goyang-si, Republic of Korea (GRID:grid.410914.9) (ISNI:0000 0004 0628 9810)